AHIMA to HHS: Clarify ICD-10 start date

Language in the last minute SGR patch, Protecting Access to Medicare Act of 2014, mandated that ICD-10 be delayed for at least a year but did not specify an exact timeline.

Calling themselves the Coalition for ICD-10, the American Health Information Management Association (AHIMA) and several other organizations are urging the Department of Health and Human Services to officially declare Oct. 1, 2015 the start date for ICD-10 so healthcare organizations can properly prepare.

In a letter to Centers for Medicare & Medicaid Services Administrator Marilyn Tavenner, the coalition argued for the quickest transition possible to the new coding system. Specifically, they wrote that ICD-10 is critical for collecting information needed to implement healthcare delivery innovations such as patient-centered medical homes and value-based purchasing.

“ICD-10 will enable better patient care through better understanding of the value of new procedures, improved disease management and an improved ability to study and understand patient outcomes, yielding benefits to patients far beyond cost savings,” according to the letter.

“While the transition to ICD-10 remains inevitable, it is extraordinarily difficult for organizations to make the proper preparations and investments without knowing the implementation date,” said AHIMA CEO Lynne Thomas Gordon, MBA in a statement. “The announcement of the new implementation date will give the industry the clarity necessary to prepare in the most cost-effective, prudent and strategic way.”

In addition to AHIMA, the signatories for the letter included the Advanced Medical Technology Association, America’s Health Insurance Plans, American Medical Informatics Association, BlueCross Blue Shield Association, College of Healthcare Information Management Executives, Health IT Now Coalition, Medical Device Manufacturers Association and 3M Health Information Systems.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.